# Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

> **NCT00977470** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 76 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT00977470
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-10
- **Primary completion:** 2015-05
- **Final completion:** 2027-12
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977470, "Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00977470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*